r. med. Ovidiu Alin Stirban Publication list Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek
K, Muel er-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D: Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress fol owing a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006, 29:2064-2071. (Impact factor 7.5) Stirban A, Negrean M. Endotheldysfunktion: Verbindung von Insulinresistenz,
Diabetes und Atherosklerose? Diabetes, Stoffwechsel und Herz, 2006, 2: 41-52.
Negrean M*, Stirban A*, Stratmann B, Gawlowski T, Horstmann T, Götting C,
Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D. Effects of low- and high-AGE (Advanced Glycation Endproducts) meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mel itus. The American Journal of Clinical Nutrition, 2007 May;85:1236-43,(*shared 1st place).
Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs. Int J Clin Pract. 2007;61:690-692. Stirban A, Negrean M, Stratmann B, Götting C, Salomon J, Kleesiek K, Tschoepe D.
Adiponectin decreases postprandial y fol owing a heat processed meal in people with type 2 diabetes mellitus - an effect prevented by benfotiamine and cooking method.Diabetes Care. 2007 Oct;30(10):2514-6. (Impact factor 7.5) Stirban A, Petrule S, Negrean M, Koschinsky T, Tschoepe D. Skin autofluorescence
increases postprandial y in human subjects. Diabetes Technol Ther. 2008 Jun;10(3):200-5. Stirban A, Tschoepe D. Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient? Is it time for polypill? Diabetes Care. 2008 Feb;31 Suppl 2:S226-8. (Impact factor 7.5) StirbanA, Tschoepe D. Cardiovascular complications in diabetes -Targets and interventions - Diabetes Care. 2008 Feb;31 Suppl 2:S215-21. Review. (Impact factor 7.5)
Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H: Single oral chal enge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007 Oct;30(10):2579-82. (Impact factor 7.5)
Gawlowski T, Stratmann B, Stirban A, Negrean M, Tschoepe D: AGEs and methylglyoxal induce apoptosis and expression of Mac-1 on neutrophils resulting in platelet-neutrophil aggregation. Thromb Res. 2007;121(1):117-26. Stirban A, Negrean A, Götting A, Gawlowski T, Stratmann B, Kleesiek K, Tschoepe D. Dietary advanced glycation end products: in vivo effects on endothelial function and adipokines. Ann N Y Acad Sci. 2008 Apr;1126:276-9. Stirban A, Rösen P, Tschoepe D. Complications of type 1 diabetes – new molecular findings. Mt Sinai J Med. 2008 Aug;75(4):328-51
Leptin Decreases Postprandial y in People with Type 2 Diabetes, an Effect Reduced by the Cooking Method. Horm Metab Res. 2008 Sep 15; 40: 896-900. Stirban A, Laude D, Elghozi JL, Sander D, Agelink M, Hilz MJ, Ziegler D. Effects of Sildenafil on Flow Mediated Dilatation and Cardiovascular Autonomic Nerve Function in Type 2 Diabetic Patients. Diabetes Metabolism Research and Reviews. 2009 Feb;25(2):136-43. Stirban A. Zycose: a new drug for the treatment of diabetes complications ? Drugs of Today (Invited review), Drugs Today (Barc). 2008 Oct;44(10):783-96. Stirban A, Tschoepe D, Stratmann B. Shifting the disease management paradigm
from glucose. Diabetes Care. 2009 Nov;32 Suppl 2:S349-52. Stirban A, Lentrodt S, Nandrean S, Pop A, Tschoepe D, Scherbaum WA. Functional
Changes in Microcirculation During Hyperbaric and Normobaric Oxygen Therapy. Hyperbaric Undersea Medicine. Undersea Hyperb Med. 2009 Sep-Oct;36(5):381-90 Stirban A, Nandrean S, Götting C, Tamler R, Pop A, Negrean M, Gawlowski T,
Stratmann B, Tschoepe D. Effects of Prescription Omega-3-Acid Ethyl Ester on Macro- and Microvascular Function in Subjects with Type 2 Diabetes Mel itus. American Journal of Clinical Nutrition. Am J Clin Nutr. 2010 Mar;91(3):808-13. Epub 2010 Jan 13. Stirban A. Nahrungs Advanced Glycation End Products. Diabetes, Stoffwechsel und Herz (Diabetes, Metabolism, and the Heart). 2009; 18:290-295. Stirban A. Die Bedeutung von AGEs und ROS bei Atherosklerose. Herz
Borza N, Stirban A. Sport bei Herzinfarkt. Diabetes aktuel 2/2010 Stirban A. Effects of ω-3 fatty acids on vascular function in subjects with type 2
Diabetes mel itus. AgroFood industry hi-tech - November/December 2010; 21: 31-33. Stirban A, Tamler R, Veresiu A. Effects of phosphodiesterase type 5 inhibitors on
endothelial function and cardiovascular autonomic nerve function in men. Journal of Men’s Health. 2011; 8(2):109–118. Stirban A. Pathogenetische Rol e der Advanced Glycation End Products (AGE). Diabetes Stoffwechsel und Herz. 2011;20(3):191-192.
Stirban A, Veresiu IA, Tamler R. Effects of Omega-3 Ethyl Esters on Macro- and
Microvascular Function in Subjects with Type 2 Diabetes Mel itus. Treatment Strategies Diabetes. 2011: 197-202.
26. L Barkai, I Gurieva, A Stirban, S Tesfaye, L Czupryniak, BN Mankovsky, V Spallone,
IA Veresiu, O Schnel , P Kempler. Microvascular complications in children and
adolescents with type 1 diabetes. Diabetes, Stoffwechsel und Herz. 2012;21:309-315 .
27. DM Cheța, E Rusu, A Stirban, C Constantin. HbA1c: Importance for Diagnosis and
Treatment. Diabetes, Stoffwechsel und Herz. In press.
28. A. Stirban, S. Del weg. Neue Methoden zur Diagnose mikrovaskulärer
Komplikationen. Diabetes Congress-Report. 2012;5:22-25. Stirban A, S Nandrean, S Kirana, C Götting, I A Veresiu, D Tschoepe.
Benfotiamine Counteracts Smoking Induced Vascular Dysfunction in Healthy Smokers.
International Journal of Vascular Medicine. 2012 (open access Journal). Stirban A, P Kotsi, K Franke, U Strijowski, W Cai, C Götting, D Tschoepe. Acute
Macrovascular Dysfunction in Patients with Type 2 Diabetes Mel itus Induced by
Ingestion of Advanced Glycated Betalactoglobulins. Diabetes Care. 2013
May;36(5):1278-82 (2012 Dec [Epub ahead of print]).
Várkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A, Jermendy G,
Kempler P. Current options and perspectives in the treatment of diabetic neuropathy.
Curr Pharm Des. 2012 Dec 26. [Epub ahead of print]
Stirban A. Therapie der diabetischen Neuropathie. Diabetes Congress-Report Stirban A. Im Fokus: mikrovaskuläre Folgeerkrankungen des Diabetes mel itus. Ärztliches Journal Reise & Medizin. 2/2013 Stirban A, Pop A, Tschoepe D. A Randomized, Double-Blind, Cross-Over,
Placebo-Controlled Trial to Investigate the Effects of a 6 Weeks Benfotiamine Treatment
on Postprandial Vascular Function and Variables of Autonomic Nerve Function in Type 2
Diabetes Mel itus. Diabetic Medicine (in press). Stirban A, Pop A, Fischer A, Heckermann S, Tschoepe D. Variability of Skin
Autofluorescence Measurement Over 6 and 12 Weeks and the Influence of Benfotiamine
Treatment. Diabetes Technology and Therapeutics (in press). Stirban A. Noninvasive Skin Fluorescence Spectroscopy for Diabetes
Screening. Journal of Diabetes Science and Technology (in press). Book chapters Pschyrembel Wörterbuch Diabetologie. Erste Auflage. Herausgeber W.A. Pschyrembel Wörterbuch Diabetologie. Zweite Auflage. Herausgeber W.A. Modern therapies for diabetes mellitus. Editor: Nicolae Hancu. Publishing house
of the Iuliu Hatieganu University, Cluj-Napoca, Romania 2008. Complications of Diabetes mellitus: Pathophysiology and Pathogenetically-based
Treatment options. Editors: Paul Thornal ey, Peter Kempler. Georg Thieme Verlag 2009.
Handbook of Vitamin C Research: Daily Requirements, Dietary Sources and Adverse Effects . Hubert Kucharski and Julek Zajac. Nova Publishers, USA, 2009
ISBN:978-1-60741-874-0 Functional Disturbaces in the Vascular Endothelium and Advanced Glycation End Products: the role of Benfotiamine. In Rett et al. Better Chances for Nerves and
Vessels, Thieme Verlag 2011, ISBN: 9783131624512. Reviewer for
“Experimental and Clinical Endocrinology and Diabetes”
“Molecular Nutrition and Food Research“
“Diabetes, Technology and Therapeutics”
PATIENT INFORMATION – HAVING A GASTROSCOPY Patient’s name: ……………………………………………………………………………………………. Your appointment is at Royal Preston Hospital (01772 522032)/Chorley Hospital (01257) 245656 Endoscopy Unit on ……………………………………. at ………………………………………………. Ga